Clinical trials: Castrate-resistant Prostate Cancer
Prostate Cancer
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen…
- Trial name
- VISION (NCT03511664)
- Testing
- 177Lu-PSMA-617, Best supportive/best standard of care
- Where
- 88 sites in United States, Belgium and 8 more
- Volunteers
- 861 people
- Sponsor
- Endocyte
Prostate Cancer Metastatic
A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
This phase I/IIa study is a multi-center, prospective, open-label study evaluating safety and biological efficacy of up to six dose levels of Osteodex of patients with metastatic castration resistant prostate cancer (CRPC).
- Trial name
- NCT01595087
- Testing
- Osteodex
- Where
- 3 sites in Sweden
- Volunteers
- 28 people
- Sponsor
- DexTech Medical AB
Disease Progression
Treatment Resistance Following Anti-cancer Therapies
The TRANSLATE study aims to better understand why tumors become resistant to standard anti-cancer therapies. New tumor biopsy and blood samples are collected after disease progression on standard-of-care anti-cancer treatment and…
- Trial name
- NCT04436120
- Testing
- De novo tumor tissue biopsy, Research blood draws
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 38 people
- Sponsor
- Pfizer
Metastatic Castration-resistant Prostate Cancer
Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC
Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer
- Trial name
- NCT03085966
- Testing
- autologous immune cell therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai AbelZeta Ltd.
Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination…
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Trial name
- KAT6 (NCT04606446)
- Testing
- PF-07248144, Fulvestrant, Letrozole
- Where
- 43 sites in United States, Australia and 3 more
- Volunteers
- 320 people
- Sponsor
- Pfizer
Prostate Cancer
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer
The objective of this study is to evaluate the safety and efficacy of a prime-boost dose schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) as measured by standard…
- Trial name
- NCT00140400
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- Volunteers
- 50 people
- Sponsor
- Cell Genesys
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured…
- Trial name
- VERACITY (NCT04844749)
- Testing
- VERU-111, Enzalutamide, Abiraterone
- Where
- 40 sites in United States
- Volunteers
- 105 people
- Sponsor
- Veru Inc.
Prostate Cancer
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients…
- Trial name
- NCT00663832
- Testing
- LBH589 (i.v. panobinostat)
- Where
- 9 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer
This is a PhaseI, open-label study, Dose-Escalation Study, where tolerated doses will be escalated to the next doses with the safety, tolerability, and PK being evaluated in metastatic castration-resistant prostate cancer (mCRPC)…
- Trial name
- NCT03074032
- Testing
- ONC1-0013B
- Where
- 2 sites in Russia
- Volunteers
- 17 people
- Sponsor
- Avionco LLC
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy of [177Lu]Lu-PSMA-617 over a change of androgen receptor-directed therapy (ARDT) treatment in prolonging radiographic progression free survival (rPFS) in Chinese metastatic…
- Trial name
- NCT05658003
- Testing
- [177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11
- Where
- 15 sites in China
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
This FIH study is designed to assess the safety, tolerability, and preliminary efficacy signals of DS9051b in participants with ACC and mCRPC.
- Trial name
- NCT07189403
- Testing
- DS9051b
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer (CRPC), Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
This Phase 1 study will evaluate the safety, tolerability, and preliminary effectiveness of AB001, an alpha-emitting radioligand targeting prostate-specific membrane antigen (PSMA), in patients with advanced prostate cancer who…
- Trial name
- ARTISAN (NCT07214961)
- Testing
- AB001
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- ARTBIO Inc.
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant…
- Trial name
- NCT02361086
- Testing
- VT-464: given orally once daily in 28 day cycles
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Innocrin Pharmaceutical
Prostatic Neoplasms
PK in Pts With HRPC & Skeletal Metastes
Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National…
- Trial name
- NCT00667537
- Testing
- Radium-223 chloride (Xofigo®, BAY88-8223) injection
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT05405439
- Testing
- TQB3823 tablets, Abiraterone acetate tablets, prednisone acetate tablets
- Where
- 23 sites in China
- Volunteers
- 39 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Prostate Cancer
EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC
This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjects with mCRPC. Phase 1 of the study will be a single-arm dose escalation study of EPI-7386 in combination with a fixed dose of…
- Trial name
- NCT05075577
- Testing
- Enzalutamide, EPI-7386 with Enzalutamide
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 77 people
- Sponsor
- ESSA Pharmaceuticals
Metastatic Prostate Cancer
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.
- Trial name
- NCT06800313
- Testing
- JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 190 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
A Study of ASP1951 in Subjects With Advanced Solid Tumors
The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or…
- Trial name
- NCT03799003
- Testing
- ASP1951, pembrolizumab
- Where
- 32 sites in United States, Canada and 2 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase I, multicenter, open-label, dose-escalation study of DSTP3086S administered as a single agent by intravenous (IV) infusion to patients with metastatic Castration-Resistant Prostate Cancer (CRPC).
- Trial name
- NCT01283373
- Testing
- DSTP3086S
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Genentech, Inc.
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT05177770
- Testing
- SRF617, etrumadenant, zimberelimab
- Where
- 9 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Coherus Oncology, Inc.